Is Eculizumab on the market?

Eculizumab (Eculizumab) is a monoclonal antibody that targets complement protein C5. Binding to this protein can prevent the activation of the complement terminal complex, which is used to treat a variety of autoimmune diseases. Eculizumab has been shown to be beneficial for patients with these rare diseases. The safety profile was similar across all diseases and considered acceptable. Eculizumab was approved by the U.S. Food and Drug Administration (FDA) in March 2007. In 2023, the European Medicines Agency (EMA) concluded that the benefits of eculizumab outweigh its risks.

Eculizumab is sold under the trade nameSoliris overseas and under the trade name Soliris in China. Eculizumab is a complement inhibitor indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria to reduce hemolysis; the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy; and the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. Eculizumab is also indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQ P4) antibody-positive.

The domestically marketed generic drug Eculizumab has been included in Class B medical insurance and is only reimbursable to eligible patients. The specification is The price of each box of 300mg (30ml) may be more than 3,000 yuan. It is understood that the price of each box of the original Eculizumab drug sold overseas is more than 6,000 US dollars (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold at home and abroad are basically the same, and the price of the original drug is still relatively expensive. There are currently no generic versions of eculizumab available on the market.